Antifungal therapeutics market to increase at a CAGR of 2.7%

The global antifungal therapeutics market was valued at $10.7 billion in 2011 and is forecast to increase at a compound annual growth rate (CAGR) of 2.7% over the next five years, to be worth a value of $12.2 billion in 2016.

Growth within the antifungal therapeutics market is set to be driven by a growing and aging population, an increase in incidence of fungal conditions, the development and approval of new products, additional indications and formulations, and an increase in worldwide market penetration.

Currently there are only 4 classes of established antifungal drugs on the market - polyenes (e.g. amphotericin B), azoles (e.g. fluconazole and itraconazole), allylamines (e.g. terbinafine) and the newly introduced echinocandins (e.g. caspofungin). Of these classes, only three are used to treat systemic fungal infections.

The US market accounted for nearly $4.5 billion in 2011 and is projected to total nearly $4.9 billion in 2016, growing at a CAGR of 1.7%.

On the other hand, the European market totalled $3.6 billion in 2011 and is projected to be worth $3.9 billion in 2016, showing a slightly lesser CAGR of 1.5%.

Developments of better diagnostics can be expected in a 5 to 10 year timescale. This will increase the available market by identifying patients who would otherwise remain undiagnosed in today's setting. In addition, better diagnostics will allow earlier diagnosis of patients, leading to better survival and longer courses of (oral) antifungal therapy.

For more information on the antifungal therapeutics market, see the latest research: Antifungal Therapeutics Market Report

Follow us on Twitter @CandMResearch